Using immunohistochemistry (IHC) and bioinformatics analyses, we showed that cancers known to be responsive to doxorubicin treatment such as diffuse large B-cell lymphoma (DLBCL) and osteosarcoma expressed higher levels of CREB3L1 than those known to be resistant to the treatment such as RCC. Here, CREB3L1 is linked to diffuse large B-cell lymphoma.